IPO
IPO filing, visualized

Frazier Life Sciences Acquisition Corp. II

FLSC · Nasdaq424B4 · Oct 14, 2026Priced Oct 13, 2026

Priced Oct 13, 2026 · latest SEC filing Nov 17, 2026.

Pinch-zoom for details.

The offering

Held in trust
$10.00
per unit, for redemptions

What the company does

Frazier Life Sciences Acquisition Corp. II is a blank-check company (SPAC). It raises cash from investors, holds it in a trust account, and then looks for a private company to merge with, which takes that company public. It says it will focus on life sciences.

Things to weigh

  • No operating business yet: the figures that matter come later, with the merger target it picks.
  • Shareholders can usually redeem their shares for the cash in trust when a merger is put to a vote.

Risks

  1. Our public shareholders may not be afforded an opportunity to vote on our proposed initial business combination, and even if we hold a vote…
  2. Your only opportunity to effect your investment decision regarding a potential business combination may be limited to the exercise of your right to…
  3. The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business…
  4. The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares…

The filing's own risk-factor headings, shortened.

Strategy

A SPAC has no business strategy of its own until it picks a company to merge with.

Source: Frazier Life Sciences Acquisition Corp. II's Form 424B4, filed with the SEC on Oct 14, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.